Atelectasis and drugs of ingredients of selexipag (a real world drug study)


Summary:

Atelectasis is found among people who take drugs with ingredients of selexipag, especially for people who are female, 60+ old , have been taking the drugs for 1 - 6 months. This phase IV clinical study is created by eHealthMe based on reports of 29,076 people who have side effects when taking drugs with ingredients of selexipag from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Selexipag, Uptravi.


On Jun, 17, 2026

29,076 people reported to have side effects when taking drugs with ingredients of selexipag.
Among them, 43 people (0.15%) have Atelectasis


What is Atelectasis?

Atelectasis (partial or complete collapse of the lung) is found to be associated with 1,458 drugs and 1,634 conditions by eHealthMe. Check the latest studies of Atelectasis.

Number of reports submitted per year:

Could drugs with ingredients of selexipag cause Atelectasis?

Time on drugs with ingredients of selexipag when people have Atelectasis *:

  • < 1 month: 22.22 %
  • 1 - 6 months: 55.56 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 11.11 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 11.11 %

Gender of people who have Atelectasis when taking drugs with ingredients of selexipag *:

  • female: 60.47 %
  • male: 39.53 %

Age of people who have Atelectasis when taking drugs with ingredients of selexipag *:

  • 0-1: 7.5 %
  • 2-9: 0.0 %
  • 10-19: 2.5 %
  • 20-29: 5.0 %
  • 30-39: 2.5 %
  • 40-49: 5.0 %
  • 50-59: 12.5 %
  • 60+: 65.0 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 33 people, 76.74%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 10 people, 23.26%
  3. Hyperlipidaemia (presence of excess lipids in the blood): 6 people, 13.95%
  4. Asthma: 3 people, 6.98%
  5. Cardiac Failure: 3 people, 6.98%
  6. Constipation: 3 people, 6.98%
  7. Insomnia (sleeplessness): 3 people, 6.98%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 6.98%
  9. Pain: 3 people, 6.98%
  10. Enlarged Prostate: 2 people, 4.65%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Opsumit: 31 people, 72.09%
  2. Adcirca: 12 people, 27.91%
  3. Adempas: 11 people, 25.58%
  4. Pantoprazole: 8 people, 18.60%
  5. Tylenol: 7 people, 16.28%
  6. Aldactone: 6 people, 13.95%
  7. Lipitor: 5 people, 11.63%
  8. Percocet: 5 people, 11.63%
  9. Potassium: 5 people, 11.63%
  10. Tadalafil: 5 people, 11.63%

Other side effects people have besides Atelectasis *:

You may use this to check any potential undetected side effects.

  1. Dyspnea (difficult or laboured breathing): 32 people, 74.42%
  2. Pleural Effusion (water on the lungs): 19 people, 44.19%
  3. Pulmonary Hypertension (increase in blood pressure in the lung artery): 18 people, 41.86%
  4. Fatigue (feeling of tiredness): 18 people, 41.86%
  5. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 17 people, 39.53%
  6. Hypotension (abnormally low blood pressure): 17 people, 39.53%
  7. Nausea (feeling of having an urge to vomit): 16 people, 37.21%
  8. Diarrhea: 16 people, 37.21%
  9. Fever: 15 people, 34.88%
  10. Pneumonia: 15 people, 34.88%

* Approximation only. Some reports may have incomplete information.


How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of selexipag, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on selexipag. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: